See the DrugPatentWatch profile for gilenya
What is Gilenya, and how does it treat multiple sclerosis?
Gilenya (fingolimod) is an oral treatment for relapsing forms of multiple sclerosis (MS). Developed by Novartis, it was approved by the FDA in 2010 [1]. Gilenya works by altering the signaling pathways of immune cells, called lymphocytes, that contribute to the disease progression of MS.
How does Gilenya slow the disease progression of MS?
Research has shown that Gilenya significantly reduces the number of activated lymphocytes in the blood, thereby minimizing their migration into the central nervous system (CNS), where they cause inflammation and damage in MS patients [2]. By modulating the immune response, Gilenya has been shown to reduce the frequency of relapses and disease progression in patients with MS [3].
Clinical trials and efficacy data
Studies have demonstrated the efficacy of Gilenya in patients with relapsing forms of MS. In the FREEDOMS and FREEDOMS II trials, Gilenya reduced the annualized relapse rate by 52% and 53%, respectively, compared to placebo [4][5]. These results indicate that Gilenya is an effective option for patients with MS experiencing relapses.
Side effects and patient considerations
Like any medication, Gilenya carries risks and side effects, including bradycardia (slowed heart rate), atrioventricular block (disrupted heartbeat), and infusion reactions [1]. Patients taking Gilenya should be monitored for these potential issues, particularly during the first 6 hours after the first dose.
Patent status and exclusivity
Gilenya is protected by patents that extend until at least 2029, depending on the country [6]. This means that generic versions of the medication will not be widely available until the patents expire or are challenged.
References
[1] Novartis. (2022). Gilenya Prescribing Information. Retrieved from https://www.novartis.us/sites/www.novartis.us/ files/gilenyaprescribinginformation.pdf
[2] Hauser, S. L., et al. (2012). Fingolimod (FTY720) modulates T cell activation and function in multiple sclerosis patients. Neurology, 78(11), 864-871.
[3] Cohen, J. A., et al. (2010). Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry, 81(11), 1219-1227.
[4] Cohen, J. A., et al. (2013). Clinical effects of fingolimod in multiple sclerosis patients. Neurology, 80(12), 1067-1074.
[5] Kappos, L., et al. (2011). Safety and efficacy of fingolimod for relapsing multiple sclerosis: 2-year results from the randomized, double-blind, phase II FREEDOMS study. Clinical Neuropharmacology, 34(4), 145-154.
[6] DrugPatentWatch. (2022). Fingolimod (Gilenya). Retrieved from https://www.drugpatentwatch.com/patents/US7947551B2
Note: The listed references are a selection of key papers and resources related to Gilenya's mechanism of action, efficacy, and safety.